Loading
Paris endocrine oncologist who was lead author of LIBRETTO-531, the trial that showed the selective RET inhibitor selpercatinib beats older kinase inhibitors as first treatment for advanced medullary thyroid cancer.
Julien Hadoux is an endocrine oncologist at Gustave Roussy who treats thyroid and neuroendocrine cancers. He was first author of the 2023 New England Journal of Medicine report of LIBRETTO-531, the phase 3 trial in which selpercatinib lengthened progression-free survival compared with cabozantinib or vandetanib in untreated RET-mutant advanced medullary thyroid cancer, establishing the selective RET inhibitor as first-line therapy.
| Title | Journal | Year |
|---|---|---|
| LIBRETTO-531: selpercatinib versus cabozantinib or vandetanib in advanced RET-mutant medullary thyroid cancer | New England Journal of Medicine | 2023 |
Shares Medullary thyroid cancer, Thyroid cancer and the tags thyroid, targeted-therapy, trialist.
Shares Medullary thyroid cancer, Thyroid cancer and the tags thyroid, targeted-therapy, trialist.
Shares Thyroid cancer and the tags thyroid, targeted-therapy.
Shares Medullary thyroid cancer, Thyroid cancer and the tags thyroid, trialist.
Shares Thyroid cancer and the tags thyroid, targeted-therapy.
Shares Gustave Roussy, Thyroid cancer and the tag thyroid.
Shares Medullary thyroid cancer, Thyroid cancer.
Shares Medullary thyroid cancer, Thyroid cancer.